DOWNLOAD REQUEST - FCF LIFE SCIENCES RESEARCH SERIES
FCF Life Sciences engages in research on recent financing trends in the Life Sciences sector, i.e. biotechnology, pharma and med-tech. FCF primarily focuses on the latest activities in the equity capital markets: Venture Capital, Initial Public Offerings (IPO) and Equity Valuations.
The findings are regularly published in:
NEWS & PRESS
FCF Biotech Venture Capital Monitor – USA 09/2022 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 09/2022”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As
Life Sciences Venture Capital Monitor – Europe 09/2022 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 09/2022”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences
European VC life sciences funding continues to decline
In 2022, the venture capital funding for life sciences in Europe continues to weaken, further widening the gap to 2021 (EUR 9.4bn vs. EUR 6.5bn). The cumulative financing volume in August 2022 falls by more
US year-to-date funding volume now below previous year’s level
After an exceptional year 2021 for venture capital funding in the US Biotech-sector, aggregated financing volumes in 2022 are for the first time lower than in 2021. During the last months funding volumes have declined
FCF Biotech Venture Capital Monitor – USA 08/2022 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 08/2022”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As
